80474-99-3

Usage

Uses

Used in Pharmaceutical Industry:
TETRAETHYL(AMINOMETHYLENE)BISPHOSPHONATE OXALATE SALT is used as a therapeutic agent for the treatment of osteoporosis and other bone diseases. It is utilized for its capacity to inhibit bone resorption by reducing the activity of osteoclasts, thereby helping to maintain bone density and strength.
Used in Bone Health Management:
TETRAETHYL(AMINOMETHYLENE)BISPHOSPHONATE OXALATE SALT is used as a bone-preserving medication to prevent bone breakdown and promote bone formation, which is crucial for maintaining overall bone health and combating conditions that lead to bone loss.
Used in Anti-inflammatory Applications:
Due to its anti-inflammatory properties, TETRAETHYL(AMINOMETHYLENE)BISPHOSPHONATE OXALATE SALT may be used in the management of inflammatory conditions affecting the skeletal system, helping to reduce inflammation and associated pain.
Used in Anti-cancer Therapy:
TETRAETHYL(AMINOMETHYLENE)BISPHOSPHONATE OXALATE SALT is used as a potential anti-cancer agent, particularly in the context of bone metastases, where it may help to prevent the breakdown of bone tissue caused by cancer cells and reduce the risk of skeletal-related events.
Administered through Oral or Intravenous Routes:
TETRAETHYL(AMINOMETHYLENE)BISPHOSPHONATE OXALATE SALT is typically administered orally or intravenously, allowing for effective systemic distribution and targeted action at sites of bone resorption. Its relative safety and tolerability when used as directed by healthcare professionals make it a preferred choice for long-term management of bone health conditions.

Upstream product

• 80474-97-1 tetraethyl (N,N-dibenzyl)aminomethyl-bis(phosphonate) 
• 77287-34-4 formamide 
• 122-52-1 triethyl phosphite 

Downstream Products

• 80475-08-7 ((Diethoxy-phosphoryl)-{[1-pyridin-2-yl-meth-(E)-ylidene]-amino}-methyl)-phosphonic acid diethyl ester 
• 89193-81-7 [[5-(2-Chloro-4-trifluoromethyl-phenoxy)-2-nitro-phenylamino]-(diethoxy-phosphoryl)-methyl]-phosphonic acid diethyl ester 
• 55422-15-6 Benzyliden-aminomethylen-bis(diethylphosphonat) 
• 71755-81-2 O,O,O,O-tetraethyl N-formylaminomethylenediphosphonate 
• 29712-28-5 aminomethylenebis(phosphonic acid) 
• 303069-19-4 tetraethyl (E)-N-(2-thiophenemethyliden)aminomethyldiphosphonate 
• 303069-16-1 tetraethyl (E)-N-(2-allyloxybenzyliden)aminomethyldiphosphonate 
• 303069-14-9 tetraethyl (E)-N-(benzyliden)aminomethyldiphosphonate 

Relevant academic research and scientific papers

Al(OH)3 facilitated synthesis of water-soluble, magnetic, radiolabelled and fluorescent hydroxyapatite nanoparticles

Magnetic and fluorescent hydroxyapatite nanoparticles were synthesised using Al(OH)3-stabilised MnFe2O4 or Fe3O4 nanoparticles as precursors. They were readily and efficiently radiolabelled with 18F. Bisphosphonate polyethylene glycol polymers were utilised to endow the nanoparticles with excellent colloidal stability in water and to incorporate cyclam for high affinity labelling with 64Cu.

New approaches towards the synthesis of 1,2,3,4-tetrahydro isoquinoline-3-phosphonic acid (TicP)

Two new strategies for the efficient synthesis of racemic 1,2,3,4-tetrahydroisoquinoline-3-phosphonic acid (TicP) (±)-2 have been developed. The first strategy involves the electron-transfer reduction of the easily obtained α,β-dehydro phosphonophenylalanine followed by a Pictet–Spengler cyclization. The second strategy involves a radical decarboxylation–phosphorylation reaction on 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic). In both strategies, the highly electrophilic N-acyliminium ion is formed as a key intermediate, and the target compound is obtained in good yield using mild reaction conditions and readily available starting materials, complementing existing methodologies and contributing to the easy accessibility of (±)-2 for further research.

1-Aminovinylphosphonate Esters as Substrates for the Diels-Alder Reaction: First Synthetic and Theoretical Study

The Diels-Alder reaction of 1-aminovinylphosphonate esters has been studied for the first time as a suitable procedure leading to quaternary carbocyclic α-aminophosphonates. The reaction is influenced by steric effects at the phosphonate functionality (bulky groups hinder the reaction) and electronic effects at the amino group (electron-withdrawing substituents increase the reaction rate). The exo/endo ratio is constant, and no influence of the solvent is observed. The experimental results have been rationalized by DFT methods.

Syntheses and evaluation of 68Ga- and 153Sm-labeled DOTA-conjugated bisphosphonate ligand for potential use in detection of skeletal metastases and management of pain arising from skeletal metastases

This article reports the syntheses and evaluation of 68Ga- and 153Sm-complexes of a new DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)-conjugated geminal bisphosphonate, DOTA-Bn-SCN-BP, for their potential uses in the early detection of skeletal metastases by imaging and palliation of pain arising from skeletal metastases, respectively. The conjugate was synthesized in high purity following an easily adaptable three-step reaction scheme. Gallium-68- and 153Sm-complexes were prepared in high yield (>98%) and showed excellent in vitro stability in phosphate-buffered saline (PBS) and human serum. Both the complexes showed high affinity for hydroxyapatite particles in in vitro binding study. In biodistribution studies carried out in normal Wistar rats, both the complexes exhibited rapid skeletal accumulation with almost no retention in any other major organ. The newly synthesized molecule DOTA-Bn-SCN-BP would therefore be a promising targeting ligand for the development of radiopharmaceuticals for both imaging skeletal metastases and palliation of pain arising out of it in patients with cancer when radiolabeled with 68Ga and 153Sm, respectively. A systematic comparative evaluation, however, showed that there was no significant improvement of skeletal accumulation of the 153Sm-DOTA-Bn-SCN-BP complex over 153Sm-DOTMP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonic acid) as the later itself demonstrated optimal properties required for an agent for bone pain palliation.

COMPOUND FOR BONE SCANNING AND USE THEREOF

The disclosure provides a compound comprising bisphosphonate functional group and chelating agent. The bisphosphonate functional group part has high affinity for bone tissue, and the chelating agent part has high affinity for metal tracer such as radioisotope. The disclosed compound could be rapidly adsorbed onto the bone surface, and could steady emit ionizing radiation. Therefore, the disclosed compound is suitable for bone scanning technology to find abnormalities in bone.

A bisphosphonate for 19F-magnetic resonance imaging

19F-magnetic resonance imaging (MRI) is a promising technique that may allow us to measure the concentration of exogenous fluorinated imaging probes quantitatively in vivo. Here, we describe the synthesis and characterisation of a novel geminal bisphosphonate (19F-BP) that contains chemically-equivalent fluorine atoms that show a single and narrow 19F resonance and a bisphosphonate group that may be used for labelling inorganic materials based in calcium phosphates and metal oxides. The potential of 19F-BP to provide contrast was analysed in vitro and in vivo using 19F-MRI. In vitro studies demonstrated the potential of 19F-BP as an MRI contrast agent in the millimolar concentration range with signal-to-noise ratios (SNR) comparable to previously reported fluorinated probes. The preliminary in vivo MRI study reported here allowed us to visualise the biodistribution of 19F-BP, showing uptake in the liver and in the bladder/urinary system areas. However, bone uptake was not observed. In addition, 19F-BP showed undesirable toxicity effects in mice that prevent further studies with this compound at the required concentrations for MRI contrast. This study highlights the importance of developing 19F MRI probes with the highest signal intensity achievable. " 2016 The Authors.

Synthesis, characterization, and antibacterial properties of a hydroxyapatite adhesive block copolymer

A novel diblock copolymer composed of bisphosphonate and pyridine oligomers has been prepared by reversible addition-fragmentation transfer (RAFT) polymerization. Ag ion was introduced into the polymer via its coordination with the pyridine groups, followed by a reduction process to obtain Ag nanoparticles with diameters of 5-15 nm measured by transmission electron microscopy (TEM). In addition, X-ray photoelectron spectroscopy (XPS) and X-ray diffraction (XRD) proved successful introduction of Ag nanoparticles into polymer. Ag nanoparticles containing polymer exhibited excellent antibacterial properties toward Lactobacillus plantarum (L. plantarum). In order to investigate its practical application as an antibacterial coating, the synthesized polymer was tethered onto hydroxyapatite (HA, main mineral component of natural bone, teeth, and most of implants for bone repair) surfaces via interaction between the polymers bisphosphonate group and HA, forming ～4 nm thick layers. Ag nanoparticles (5-15 nm in diameter) uniformly distributed around the HA particles were fabricated following the above process. The ability of the coating to kill the bacteria L. plantarum was determined, which revealed strong antibacterial properties.

PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS

The present invention relates to phosphonated Rifamycins, and methods of making and using such compounds. These compounds are useful as antibiotics for prophylaxis and/or the treatment of bone and joint infections, especially for the prophylaxis and/or treatment of osteomyelitis.

PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS

The present invention relates to phosphonated Rifamycins, and methods of making and using such compounds. These compounds are useful as antibiotics for prophylaxis and/or the treatment of bone and joint infections, especially for the prophylaxis and/or treatment of osteomyelitis.

PHOSPHONATED GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS

The present invention is directed to antimicrobial compounds which have an affinity for binding bones. More particularly, the invention is directed to phosphonated derivatives of glycopeptide or lipoglycopeptide antibiotics. These compounds are useful as antibiotics for the prevention or treatment of bone and joint infections, especially for the prevention and treatment of osteomyelitis.